Publication | Closed Access

Phase II clinical trial of metronomic chemotherapy with combined irinotecan and tegafur–gimeracil–oteracil potassium in metastatic and recurrent breast cancer

Breast OncologyOncologyMedicineMetronomic TherapyRecurrent Breast CancerBreast CancerPharmacotherapyAnti-cancer AgentMetronomic ChemotherapyCancer TreatmentPharmacologyTegafur–gimeracil–oteracil Potassium